Oddo BHF Asset Management Sas Purchases 11,575 Shares of Gilead Sciences, Inc. $GILD

Oddo BHF Asset Management Sas lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 141,289 shares of the biopharmaceutical company’s stock after purchasing an additional 11,575 shares during the period. Oddo BHF Asset Management Sas’ holdings in Gilead Sciences were worth $19,691,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Brighton Jones LLC raised its position in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $215,000. Sivia Capital Partners LLC increased its stake in shares of Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 602 shares during the period. Ieq Capital LLC increased its stake in shares of Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after buying an additional 12,705 shares during the period. Finally, Diversify Advisory Services LLC raised its holdings in shares of Gilead Sciences by 18.6% during the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after acquiring an additional 674 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Down 1.2%

GILD opened at $132.73 on Thursday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The stock has a market cap of $164.79 billion, a PE ratio of 18.08 and a beta of 0.32. The business has a 50 day moving average of $129.68 and a 200-day moving average of $135.84.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: UBS analyst Michael Yee reiterated a Buy rating and maintained a $175 price target, citing Gilead’s long-acting HIV pipeline and advances in pre-exposure prophylaxis (PrEP) as sources of durable growth. Michael Yee Reiterates Buy on Gilead
• Positive Sentiment: The earnings preview highlights continued strength in Gilead’s HIV franchise, rising expectations for Yeztugo, and progress in oncology. These businesses could help support revenue growth and investor sentiment if management provides constructive guidance. Gilead to Report Q2 Earnings
• Neutral Sentiment: Gilead’s CAR-T therapies remain established products, but off-the-shelf developers are targeting market segments that approved therapies do not fully address. This could expand the broader CAR-T market while also increasing competitive pressure over time. BMS and Gilead Rule in the CAR-T Space
• Negative Sentiment: Barclays lowered its Gilead price target from $155 to $145 and assigned an Equal Weight rating, signaling more limited near-term upside despite the target remaining above the current trading level. Barclays Gilead Price Target Update
• Negative Sentiment: Analyst previews warn that Gilead may report a decline in second-quarter earnings and does not appear to have the usual combination of positive earnings revisions and estimate-beat indicators. Competitive pressure in Cell Therapy is an additional concern heading into the report. Analysts Estimate Gilead to Report a Decline in Earnings
• Negative Sentiment: Atea Pharmaceuticals said its hepatitis C combination therapy matched Gilead’s drug in a pivotal Phase 3 trial. If approved, a competing oral regimen could threaten Gilead’s hepatitis C franchise, although commercialization and regulatory risks remain. Atea Hepatitis C Phase 3 Trial

Insider Activity

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the sale, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at $76,674,826.57. This represents a 2.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 67,000 shares of company stock worth $8,687,140. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on GILD. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Rothschild & Co Redburn reduced their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Morgan Stanley decreased their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday. The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Finally, Citigroup lifted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $157.93.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.